Patents by Inventor Henry H. Lu

Henry H. Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridyl substituted heterocycles useful for treating or preventing HCV infection
    Patent number: 7714137
    Abstract: The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: May 11, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Dane Goff, John Partridge, Henry H. Lu
  • Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection
    Publication number: 20080171871
    Abstract: The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.
    Type: Application
    Filed: December 20, 2007
    Publication date: July 17, 2008
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder Singh, Dane Goff, John Partridge, Henry H. Lu
  • HCV inhibitors and methods of using them
    Patent number: 7358259
    Abstract: The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a mammal.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: April 15, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sambaiah Thota, Ankush Argade, Rajinder Singh, Henry H. Lu, Peiyong Huang
  • Pyridyl substituted heterocycles useful for treating or preventing HCV infection
    Patent number: 7332602
    Abstract: The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: February 19, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Dane Goff, John Partridge, Henry H. Lu
  • Pyridyl substituted heterocycles useful for treating or preventing HCV infection
    Patent number: 7157473
    Abstract: The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: January 2, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Dane Goff, John Partridge, Henry H. Lu
  • Methods and compositions for the identification of anti-poxvirus agents
    Patent number: 7132234
    Abstract: The invention provides methods for identifying an anti-poxviral agents. In many embodiments, the methods involve contacting a poxviral p28 polypeptide with a candidate agent, and determining an effect of the agent on a ubiquitin ligase activity of the p28 polypeptide. The effect of the agent may be determined using a variety of different cell based or biochemical assays, such as polyubiquitylation assays and cell viability assays. The invention also provides methods for modulating poxvirus pathogenicity in a cell, and methods of treating an individual infected with a poxvirus. The subject methods find use in a variety of drug discovery, research and military applications.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: November 7, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Henry H. Lu, Jianing Huang, Donald G. Payan
  • Compositions and methods for screening and identifying anti-HCV agents
    Publication number: 20030219723
    Abstract: The field of the invention is methods for screening for effector peptides, polypeptides and fragments thereof and RNA molecules selected inside living cells that have anti-HCV activity.
    Type: Application
    Filed: May 20, 2002
    Publication date: November 27, 2003
    Inventors: Henry H. Lu, Peiyong Huang, Todd Kinsella, Anthony Martinez